- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01547351
Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire (ARMS)
Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire - A Phase 4 Pilot Study
This Phase 4 pilot cross-sectional descriptive/exploratory study is to be conducted in clinical practice settings (including MS (Multiple sclerosis) specialty clinics, general neurology practices, or other academic or private practice settings) in the United States to assess the psychometric properties of the ARMS questionnaire in approximately 100 adult patients with MS who are experiencing a confirmed relapse, as identified by the investigator or designee at each site. Neither efficacy nor safety of treatment will be evaluated in this study.
The ARMS questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page. Part 1 is designed to evaluate the patient's relapse symptoms and how the symptoms affect daily activities and overall function, as well as patient's response to past treatments for previous relapses, as a means of guiding treatment selection. Part 2 is designed to evaluate treatment response in terms of symptom relief and functioning, as well as treatment tolerability. Part 1 of the survey is to be completed when the patient presents with new relapse of MS. Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse of MS. Treatment for relapse will be at the sole discretion of the investigator.
Studieöversikt
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna
- Tanner Center and Foundation for MS
-
-
California
-
Oceanside, California, Förenta staterna
- Neurology Center
-
-
Florida
-
Hollywood, Florida, Förenta staterna
- Infinity Clinical Research
-
Orlando, Florida, Förenta staterna
- McCare Center Neurology Services
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna
- Neurology Center of Fairfax
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Informed consent and HIPAA authorization must be obtained from the patient prior to any study-related procedures.
- Patient is ≥ 18 years of age at the time of participation
- Patient has confirmed MS relapse.
- Patient must have been treated with oral or IV corticosteroids for their previous relapse.
- Willingness to comply with all procedures and assessments.
Exclusion Criteria:
- Patient has pseudorelapse.
- Patient was treated with any therapies other than corticosteroids for their previous relapse.
- Any other condition which, in the opinion of the investigator, would not allow proper completion of this study.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
ARMS Questionnaire Group
Patients with confirmed multiple sclerosis relapse who are willing to participate in the ARMS questionnaire.
These patients could not have been treated with any therapies other than oral or intravenous corticosteroids for their previous relapse.
|
The ARMS Questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page.
Eligible patients will be administered part 1 of the survey when the patient presents with new relapse.
Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Total Composite Score (TCS)
Tidsram: After relapse treatment (1 month ± 1 week)
|
Total composite score is calculated from three interrelated questions on part 2 of the ARMS questionnaire (to be completed 1 month ± 1 week after relapse treatment).
|
After relapse treatment (1 month ± 1 week)
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- QSC02-ARMS-01
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Multipel skleros
-
Centre Hospitalier Universitaire de NīmesAvslutadMonckeberg Medial Calcific SclerosisFrankrike
-
Assistance Publique - Hôpitaux de ParisOkändArteriosclerosis Obliterans | Diabetiska vaskulära sjukdomar | Monckeberg Medial Calcific SclerosisFrankrike
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeKlassiskt Hodgkin lymfom | Lymfocytrikt klassiskt Hodgkin-lymfom | Ann Arbor stadium IB Hodgkin lymfom | Ann Arbor stadium II Hodgkin lymfom | Ann Arbor stadium IIA Hodgkin lymfom | Ann Arbor stadium IIB Hodgkin lymfom | Ann Arbor stadium I Hodgkin lymfom | Ann Arbor Steg I blandad cellularitet Klassiskt... och andra villkorFörenta staterna
Kliniska prövningar på ARMS Questionnaire
-
Hôpital NOVOAvslutadHemiplegi och/eller hemipares efter strokeFrankrike
-
Stanford UniversityNational Center for Complementary and Integrative Health (NCCIH)Aktiv, inte rekryterandePrebiotikaFörenta staterna
-
Bioagile Therapeutics Pvt. Ltd.Avslutad
-
Washington University School of MedicineAktiv, inte rekryterandeAlzheimers sjukdom | Demens av AlzheimertypFörenta staterna
-
Riyadh Elm UniversityHar inte rekryterat ännuParodontala sjukdomar | Malocklusion, Angle's Class | Tandträngsel, Interproximal emaljreduktionSaudiarabien
-
Shandong Suncadia Medicine Co., Ltd.Avslutad
-
Novartis PharmaceuticalsAvslutadKronisk spontan urtikariaFörenta staterna, Belgien, Storbritannien, Tyskland, Ungern, Spanien, Frankrike, Kalkon, Kanada, Tjeckien, Nederländerna, Polen, Japan, Ryska Federationen, Argentina, Danmark, Slovakien
-
Cyclacel Pharmaceuticals, Inc.AvslutadAkut myeloid leukemiFörenta staterna
-
The Hospital for Sick ChildrenHar inte rekryterat ännuEpilepsi; BeslagKanada
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); Swim Across America; Atrium Health Levine...RekryteringAkut myeloid leukemiFörenta staterna